By Lynne Taylor. Free news subscriptions Free RSS feeds. Can price-cutting take the shine off generics? Indian nod for a Central Drugs Authority. Pricing set to be a huge issue in Asian nations. Get the latest pharma news delivered to your inbox. A valid email address is required. Subscribe for free. It showed comparable preclinical, safety and efficacy data to Roche's monoclonal antibody, and is licensed for the treatment of chronic lymphocytic lymphoma CLL - for which MabThera is widely used - as well as non-Hodgkin's follicular lymphoma and diffuse large B-cell lymphoma.
The biosimilar has also been approved for use in adults with severe rheumatoid arthritis and in combination with glucocorticoids for the treatment of granulomatosis with poylangiitis and micropscopic polyangiitis. Roche's blockbuster even saw slight growth in , despite increasing competition and pricing pressure, but the firm hopes to combat the advent of biosimilars with a flurry of new launches in the coming year, including lung cancer drug Alecensa alectinib and multiple sclerosis treatment Ocrevus ocrelizumab.
Truxima is not the first biosimilar Mundipharma has licensed for EU marketing, having launched Remsima , a biosimilar version of Janssen's blockbuster arthritis treatment Remicade infliximab , in Article by Rebecca Clifford. Please login to the form below.
0コメント